Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550271 · ClinicalTrials.gov registry record
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
A clinical trial, sponsored by AgelessRx.
- Completed
- Registry status
- 67
- Enrollment target
NCT06550271 is a clinical trial that has completed, run by AgelessRx. The registered enrollment target is 67 participants.
The verdict
NCT06550271 has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
Interventions
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06550271
The ClinicalTrials.gov registry entry for NCT06550271 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AgelessRx, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapamycin is the first listed.
NCT06550271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06550271 about?
NCT06550271 is a clinical study titled "The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals". This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
What is the current status of trial NCT06550271?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2023-04-25. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT06550271?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT06550271?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.